Beijing Rexiu

Rexiu Biotech is a Beijing-based biotechnology company specializing in the development and commercialization of innovative diagnostic products based on heat shock protein 90 alpha (HSP90α). Founded by Professor Luo Yongzhang of Tsinghua University, the company pioneered the use of HSP90α as a tumor marker, leading to the development of the world's first HSP90α quantitative detection kit. Their products are primarily utilized for the early screening, auxiliary diagnosis, and treatment monitoring of various malignancies, including lung and liver cancer. Rexiu Biotech operates as a high-tech enterprise integrating R&D, production, and sales of advanced in vitro diagnostic (IVD) solutions.